BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 30, 2002
View Archived Issues
HuMax-CD4 does not meet primary endpoint in phase II rheumatoid arthritis trial
Read More
ERbeta agonist isolated from plant by Merck researchers
Read More
Novel CB2 agonists and their use in pain, glaucoma, epilepsy, etc.
Read More
Spanish lab reveals new magnetic resonance contrast agents
Read More
UCB acquires Cardiome's antitussive program
Read More
Phase I TNFerade trial in soft tissue sarcoma fully enrolled
Read More
Tanabe AAI signs development and licensing agreements for first three compounds
Read More
Wyeth to evaluate BioVex's NeuroVEX vectors
Read More
Bone-targeted Src tyrosine kinase inhibitor may have use in bone metastases
Read More
PT-141 shows phase I potential for female sexual dysfunction
Read More
Cerebril IND filed for hemorrhagic stroke due to cerebral amyloid angiopathy
Read More
Cel-Sci signs agreement for evaluation of CEL-1000 against herpes
Read More
Bristol-Myers Squibb to reacquire U.S. copromotion rights for Tequin from Schering-Plough
Read More
FeRx regains rights to MTC-DOX following termination of Elan joint venture
Read More
Small-molecule inhibitor of RANK-RANKL interaction presented at ASBMR meeting
Read More
Preclinical data support use of KRN-1493 in secondary hyperparathyroidism
Read More
Potent, selective EP4 agonists identified at Pfizer, effective in osteopenic rat model
Read More
AP-23588 exerts both antiresorptive and bone formation-enhancing effects
Read More
NNC-55-0118 characterized as beta-cell-selective potassium channel opener
Read More
Dong-A selects oxazolidinone DA-7867 as development candidate
Read More
Inhibitors of IL-1beta and/or TNF-alpha prepared and tested at Sankyo
Read More
BMS identifies 5-HT2 receptor modulators for obesity and other disorders
Read More
Biaryl LDL receptor upregulators reported in Takeda patent
Read More
NNRTI with potent activity against mutant and wild-type enzymes
Read More
Zofimarin-related antifungal agent examined in vitro and in vivo at Sankyo
Read More
BMS selects clinical development candidate for RSV infection
Read More
Antibacterial activity and toxicity of CP-5609, a new carbapenem, reported at ICAAC
Read More
